

Application No. 09/654,276
Amendment dated November 12, 2004
Reply to Final Office Action of August 11, 2004

REMARKS

Entry of the Amendment is respectfully requested. Applicants submit the Amendment places the application in condition for allowance and raises no issues not previously considered by the Examiner.

Claims 1, 5, 16, and 19 have been amended to further clarify the invention. After entry of the Amendment, claims 1-3, 5, 6, 9, 10, and 16-24 will be pending.

Enablement

Claims 1-3, 5, 6, 9, 10, and 16-24 were rejected under 35 U.S.C. § 112, first paragraph, as lacking enablement. Applicants respectfully traverse this rejection.

Without acquiescing to the rejection and solely to expedite prosecution, Applicants have directed the claims to fetal, autologous, or allogeneic mammalian cells. Applicants reserve the right to pursue the canceled subject matter in a continuation or other application.

The Action acknowledges the scope of enablement includes fetal cardiomyocytes without any limitation to origin and autologous cardiomyocytes. The Examiner, however, alleges the specification does not enable matrices comprising allogeneic or xenogeneic cells. The Examiner asserts the specification does not provide any guidance as to measures or methods necessary to prevent destructive allogeneic or xenogeneic immune responses following transplantation of matrices containing allogeneic or xenogeneic tissue. Applicants do not agree.

"Because an enabling disclosure by definition turns upon the objective understanding of a skilled artisan, the enablement requirement can be met by reference to the knowledge of one of ordinary skill in the relevant art." *Bayer AG v. Schein Pharmaceuticals*, 301 F3d 1306, 1314 (Fed. Cir. 2002). Moreover, a specification need not disclose what is well known in the art. *Hybridtech Inc. v. Monoclonal Antibodies Inc.*, 802 F2d 1367, 1385 (Fed. Cir. 1986). What is well known is best omitted. *In re Buchner*, 929 F.2d 660, 661 (Fed. Cir. 1991).

At the time of filing, mechanisms of immune response and transplant rejection were known and the use of immunosuppressive drugs to prevent rejection of transplanted tissue was a standard clinical treatment known to one of skill in the art. See, for example, Superdock and Helderman, 1993, *Sem. Resp. Infect.*, 8:52-159 (copy enclosed) at page 152:

Application No. 09/654,276
Amendment dated November 12, 2004
Reply to Final Office Action of August 11, 2004

Advances in immunology, tissue, typing, and pharmaceuticals have had a dramatic impact on success rates and have allowed the successful transplantation of organs between genetically non-identical people...As transplantation has become so successful in the treatment of end-stage renal disease, organ transplantation has now become a form of replacement therapy for end-stage liver, lung, heart, and bone marrow disease. In addition, pancreatic transplantation is now an accepted therapy for insulin-dependent diabetes mellitus.

Superdock and Helderman, for example, disclose the use of azathioprine, glucocorticoids, cyclosporine A, cyclosporine G, FK506, rapamycin, mycophenolic acid, mycophenolate mofetil (RS-61443), mizoribine, brequinar sodium, and deoxyspergualaine as immunosuppressants for long-term management of transplant recipients and discuss the immunosuppressant mechanisms of these immunosuppressive agents.

Woodley et al., 1990, *Heart Transplantation*, 8:83-96 (copy enclosed), for example, teach phases of immunosuppression associated with cardiac transplantation, an algorithmic approach to cardiac allograft rejection and treatment regime (Figure 4 at page 92), use and dosages of immunosuppressive agents, such as cyclosporine, azathioprine, corticosteroids, ATG/ALG, monoclonal antibody OKT3, vincristine, and methotrexate, for early prophylaxis, chronic maintenance, and rejection treatment (Table 1 at page 85, Figure 2 at page 86, and Figure 3 at page 87), pharmacology of the immunosuppressive agents including route of administration, side effects, and drug interactions (Table 2 at page 85), and mechanism of action of the immunosuppressive agents (Table 3 at page 86).

Accordingly, one of skill in the art would reasonably predict that biografts comprising allogeneic cells could be used with standard immunosuppressive treatments known in the art to overcome rejection of the allogeneic cells.

Citing *Genentech v. Novo Nordisk*, 42USPQ2d 1001 (CAFC 1997), the Action states that when there is no disclosure of any of the conditions under which a process can be carried out, undue experimentation is required. Therefore, the Examiner alleges there is a failure to meet the enablement requirement that cannot be rectified by asserting that

Application No. 09/654,276
Amendment dated November 12, 2004
Reply to Final Office Action of August 11, 2004

all the disclosure related to measures and methods to prevent allogeneic immune responses is within the skill of the art. Applicants do not agree.

In *Genentech v. Novo Nordisk*, the fact that no one had been able to produce any human protein via cleavable fusion expression as of the application date of the patent in suit undermined the patentee's contention that the specification's disclosure of a DNA sequence encoding human growth hormone and a single example enzyme and its cleavage site, without more, would have enabled one skilled in art to use the claimed cleavable fusion expression method to make hGH without undue experimentation.

In contrast, mechanisms of immune response and transplant rejection were known and the use of immunosuppressive drugs to prevent rejection of transplanted tissue was a standard clinical treatment known to one of skill in the art. Therefore, one of ordinary skill in the art would reasonably predict that biografts comprising allogeneic cells could be used with standard immunosuppressive treatments known in the art to overcome rejection of the allogeneic cells.

In view of the forgoing, Applicants submit one of ordinary skill in the art would have been able to make and use biografts comprising fetal, autologous, or allogeneic cells without undue experimentation. Withdrawal of the rejection is respectfully requested.

NOV-12-04 14:55 FROM Merchant & Gould

6123329081

T-164 P.011/011 F-535

Application No. 09/654,276
Amendment dated November 12, 2004
Reply to Final Office Action of August 11, 2004

Conclusion

In light of the forgoing Amendment and Remarks, Applicants' assert the claims are in condition for allowance. Early notice of allowable claims is requested. The Examiner is invited to telephone the undersigned attorney for clarification of any of these Remarks or Amendments, or to otherwise speed prosecution of this case.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: November 12, 2004



Gregory A. Sebald
Reg. No. 33,280
GAS:EED:lek

